{"id":44333,"date":"2022-05-25T14:01:28","date_gmt":"2022-05-25T12:01:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/"},"modified":"2022-05-25T14:01:28","modified_gmt":"2022-05-25T12:01:28","slug":"iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/","title":{"rendered":"iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs"},"content":{"rendered":"
\n

\nPartnership to focus on manufacturing clinical materials for future clinical studies<\/i>\n<\/p>\n

PHILADELPHIA–(BUSINESS WIRE)–iECURE<\/a><\/b>, a gene editing company focused on mutation-agnostic in vivo<\/i> gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM will produce and supply Good Manufacturing Practices (GMP)-grade adeno-associated virus (AAV) for use in iECURE\u2019s future clinical studies to enable development of iECURE\u2019s programs with the shared mission of accelerating the availability of these potential treatments to the patients.\n<\/p>\n

<\/a><\/p>\n

\n\u201cOur approach to gene editing relies on highly complex manufacturing processes, and we are eager to establish partnerships to ensure a reliable supply of GMP materials for future clinical development,\u201d said Paul Firuta, Chief Operating Officer of iECURE. \u201cCBM was able to offer us significant amount of guaranteed capacity with scheduling flexibility and we are confident that they will be a strong partner with their state-of-the-art facilities and end-to end capabilities.\u201d\n<\/p>\n

\n\u201ciECURE\u2019s approach to gene editing is quite innovative and has the potential to bring significant hope to patients and families facing devastating diagnoses,\u201d said Audrey Greenberg, Chief Business Officer and Co-Founder of CBM. \u201cOur ability to provide customizable clinical and commercial GMP manufacturing solutions integrated with industry-leading comprehensive in-process testing, quality control, and lot release programs allows us to support our partners like iECURE through the entirety of their product lifecycle and is aligned with our mission to bring life changing medicines to patients in need.\u201d\n<\/p>\n

\nAbout iECURE<\/b>\n<\/p>\n

\niECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo<\/i> gene insertion, or knock-in, editing for the treatment of monogenic liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team\u2019s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania\u2019s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP\u2019s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates. For more information, visit www.iecure.com<\/a><\/i><\/b> and follow on LinkedIn<\/a><\/i><\/b>.\n<\/p>\n

\nAbout Center for Breakthrough Medicines (CBM)<\/b>\n<\/p>\n

\nCBM is a cell and gene therapy contract development and manufacturing organization (CDMO) based in the heart of Philadelphia\u2019s Cellicon Valley. CBM offers pre-clinical through commercial manufacturing capabilities including process development, plasmid DNA, viral vector, cell therapy and a full suite of testing and analytical capabilities. Through a single-source, end-to-end solution, CBM accelerates time to market without compromising quality.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:
\n
David Garrett
\n
dgarrett@iecure.com<\/a><\/i><\/b>\n<\/p>\n

\nMedia:
\n
Danielle Cantey
\n
Canale Communications
\n
danielle.cantey@canalecomm.com<\/a><\/i><\/b>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Partnership to focus on manufacturing clinical materials for future clinical studies PHILADELPHIA–(BUSINESS WIRE)–iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44333","6":"format-standard","7":"category-industry"},"yoast_head":"\niECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Partnership to focus on manufacturing clinical materials for future clinical studies PHILADELPHIA–(BUSINESS WIRE)–iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-25T12:01:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220525005247\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs\",\"datePublished\":\"2022-05-25T12:01:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/\"},\"wordCount\":536,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005247\\\/en\\\/1310882\\\/21\\\/iECURE_Logo_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/\",\"name\":\"iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005247\\\/en\\\/1310882\\\/21\\\/iECURE_Logo_%282%29.jpg\",\"datePublished\":\"2022-05-25T12:01:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005247\\\/en\\\/1310882\\\/21\\\/iECURE_Logo_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005247\\\/en\\\/1310882\\\/21\\\/iECURE_Logo_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/","og_locale":"en_US","og_type":"article","og_title":"iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs - Pharma Trend","og_description":"Partnership to focus on manufacturing clinical materials for future clinical studies PHILADELPHIA–(BUSINESS WIRE)–iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-25T12:01:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220525005247\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs","datePublished":"2022-05-25T12:01:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/"},"wordCount":536,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220525005247\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/","url":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/","name":"iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220525005247\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg","datePublished":"2022-05-25T12:01:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220525005247\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220525005247\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44333"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44333\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}